Correlation of anti-acetylcholine receptor antibody levels and long-term outcomes of juvenile myasthenia gravis in Taiwan: a case control study

CURRENT STATUS: ACCEPTED

ORCiD: https://orcid.org/0000-0003-2578-1256

cheng che chou
Chang Gung Memorial Hospital Keelung Branch

I Chen Su
Chang Gung Memorial Hospital Linkou Branch

I Jun Chou
Chang Gung Memorial Hospital Linkou Branch

Jainn Jim LIN
Chang Gung Memorial Hospital Linkou Branch

Shih Yun Lan
Regions Hospital

Yi Shan Wang
Chang Gung Memorial Hospital Linkou Branch

Shu Sing Kong
Taipei Medical University Shuang Ho Hospital

Yun Ju Chen
Chang Gung Memorial Hospital Linkou Branch

Meng Ying Hsieh
Chang Gung Memorial Hospital Linkou Branch

Po Cheng Hung
Chang Gung Memorial Hospital Linkou Branch

Huei Shyong Wang
Chang Gung Memorial Hospital Linkou Branch
Subject Areas
Internal Medicine Specialties

Keywords
Myasthenia gravis; juvenile; Asia; acetylcholine receptors; Graves’ disease; outcome assessment
Abstract

Background

Myasthenia gravis is the most common disease affecting the neuromuscular junction. The most common etiology among patients with juvenile myasthenia gravis is the production of antibodies against the acetylcholine receptor. However, the clinical outcome in relation to serum levels of anti-acetylcholine receptor antibodies in juvenile myasthenia gravis has rarely been discussed. We aimed to analyze the correlation between the presence of anti-acetylcholine receptor antibodies and outcome in juvenile myasthenia gravis.

Methods

Patients diagnosed with juvenile myasthenia gravis younger than of 20 years of age were retrospectively recruited from January 1995 to February 2017 in a tertiary referral medical center. According to the Myasthenia Gravis Foundation of America outcome scale, the primary outcome was complete symptom remission and cessation of medications for at least 1 year measured 2 years after diagnosis. Secondary outcome was complete symptom remission at the last outpatient clinic.

Results

A total of 54 patients were followed up for over 2 years. Nine patients (9/54, 16.7%) achieved complete remission without medication use at two years after diagnosis. Thirteen (24.1%) patients achieved complete remission during longer follow-up periods. Those with negative anti-acetylcholine receptor antibodies were more likely to achieve complete remission at 2 years (6/15 40% vs. 3/39 7.7%, 95% Confidence interval CI 1.670 to 38.323) and at the last outpatient clinic follow-up (8/15 53.3% vs. 5/39 12.8%, 95% CI 2.367 to 20.704). Thirteen patients with comorbid autoimmune thyroid diseases were older than those without disease (11.8 ± 5.8 years old vs. 8.0 ± 6.3 years old, 95% CI 0.018 to 7.33). Moreover, patients negative for anti-acetylcholine receptor antibodies were less likely comorbid with autoimmune thyroid disease (1/35 2.9% vs. 12/71 16.9%, 95% CI 0.018 to 1.161).

Conclusions

Juvenile myasthenia gravis patients without anti-acetylcholine antibodies exhibited significantly increased complete remission rates and a reduced likelihood of comorbid autoimmune thyroid
diseases compared with those with anti-acetylcholine receptor antibodies.

Background
Myasthenia gravis (MG) is the most common autoimmune disease affecting the neuromuscular junction. Juvenile onset myasthenia gravis (JMG) accounts for 11-24% of all patients with MG [1]. Among patients with autoimmune JMG, the most common antibody observed is the anti-acetylcholine receptor antibody. Antibody-positive patients account for 50% to 90% of JMG cases [2,3]. Other antibodies against muscle-specific kinase (MUSK) [4], cortactin and lipoprotein receptor-related protein 4 are also reported [5]. These antibodies are used to help clinical diagnosis of myasthenia gravis; however, whether these antibodies can predict outcome is still debated.

Regarding overall outcome, JMG patients demonstrated an increased remission rate compared with adult-onset MG, ranging from 11% to 60% [1,2,6,7]. Prepubertal onset MG exhibits an increased remission rate compared with postpuberty onset MG [2]. Patient weakness exclusively limited to the ocular area is associated with a better outcome compared with the presentation of general weakness [8]. The presence of antibodies other than anti-acetylcholine receptor antibodies, such as anti-MUSK antibody, is associated with poor outcome [4]. However, serum levels of anti-acetylcholine receptor antibodies in relation with the clinical outcome in JMG have rarely been discussed [1,9]. Andrew et al. reported that remission rate did not differ between seropositive and seronegative patients [1]. However, the study did not present the seropositive and seronegative cut-off levels, which varied from 0.2 to 0.5 among studies. The timing of antibody measurement was not determined. Another study had only few patients for analysis of correlation of outcome and antibodies level [9]. Anti-acetylcholine receptor antibody levels are frequently assessed during the initial presentation for clinical diagnosis, and levels correlate with clinical severity [10]. Whether anti-acetylcholine receptor antibodies predict outcome remains unknown. The aim of this study was to analyze the predictive value of the presence of anti-acetylcholine receptor antibodies for outcome among patients with JMG.

Methods
2.1 Setting and participants
Patients under the age of 20 years diagnosed with JMG from January 1995 to October 2015 in Chang
Gung Memorial Hospital, Linko branch, which is a tertiary referral medical center, were retrospectively reviewed using medical records. The diagnosis was made by at least one of the following specialists: pediatric neurologist, ophthalmologist, or neurologist. Another pediatric neurologist would further confirm the diagnosis. JMG patients were clinically defined by the presence of at least one clinical symptoms of ptosis or proximal weakness plus positive test results for at least one of the following assessments: (1) responsive to Tensilon test or anti-cholinergic regimen, (2) decremental response to the 3 Hz repetitive stimulation test, and (3) presence of serum anti-acetylcholine receptor antibodies (≥ 0.5 nanomoles per liter [nmol/L]). Patients were excluded if electromyography or muscle biopsy reports indicated other neuromuscular diseases. This study obtained ethical approval from the institutional review board of the Chang Gung Memorial Hospital (IRB No 201700494B0). This is a retrospective study, no inform consent was made.

2.2 Data used in the study

Data regarding sex, age at onset, clinical symptoms and maximum disease severity, history pharmacological treatment, family history and other interventions were collected. Age at onset was defined as the age at the time of the first manifestation of the disease or any neurological sign indicative of MG.

2.3 Disease severity and outcome measure

Clinical severity and outcome measures were determined according to the Myasthenia Gravis Foundation of America recommendation [11]. The severities were classified as follows: Class I, ocular MG and all other muscle strength is normal; Class II, mild weakness affecting muscles other than ocular muscles; Class III, moderate weakness affecting muscles other than ocular muscles; Class IV, severe weakness affecting muscles other than ocular muscles; and Class V, intubation with or without mechanical ventilation. Primary outcome was measured based on the complete symptom remission (CSR) rate, which is the cessation of medication for at least 1 year without symptoms. The results were measured 2 years after diagnosis. The secondary outcome was the change in symptoms between initial manifestation and at the last outpatient clinic, wherein residual symptoms were observed. The change in symptoms was categorized as (1) complete remission and discontinuation of
all drug therapy; (2) good improvement but continuation of drug therapy at the same or lower dosage; (3) unchanged, slight subjective and/or objective improvement but large doses of medication are necessary; or (4) worse.

2.4 Laboratory antibody measurements

All blood specimens were analyzed in the clinical laboratory. Test results were collected from the central database. In this laboratory, internal and external quality control procedures for biochemical data yielded consistently satisfactory results. External quality control was ensured by observing the guidelines promulgated by the College of American Pathologist and the National Quality Control Program of the Government of Taiwan.

Antibodies against acetylcholine receptor antibody were tested as described previously in serum samples collected using the radioimmunoassay kit according to the RSR manufacturer’s instructions at UK (http://www.rsrltd.com). Serology tests were performed at the initial stage for diagnosis. The presence of antibodies was double checked if symptoms were not controlled during treatment course. The peak level of anti-acetylcholine receptor antibodies between diagnosis date and the end of follow-up was chosen as the primary exposure variable. Using the highest serum level, we categorized the test results as seronegative if the antibody levels were < 0.2 nmol/L, equivocal if levels were 0.2 ~ 0.49 nmol/L, and positive if levels were ≥ 0.5 nmol/L. Blood samples were examined for the presence of anti-Musky antibodies for patients with systemic myasthenia gravis with persistently negative antibodies against the acetylcholine receptor. Tests for other MG-related antibodies were not available in our center.

2.5 Statistical analysis

Fisher’s exact test was performed to analyze differences in baseline characteristics between patient subgroups when comparing categorical variables and the correlation between anti-acetylcholine antibodies and outcome.

To determine the optimum discriminant value of anti-acetylcholine receptor antibodies to predict the clinical outcome in JMG, we performed receiver operator characteristic (ROC) curves. Sensitivity, specificity, positive predictive values (PPV) and negative predictive values (NPV) were calculated for
the outcome corresponding to different cut-off values of anti-acetylcholine receptor antibodies.

Logistic regression was used for analysis of a dataset in which there are one or more independent variables that determine an outcome.

A p-value of less than 0.05 using two-tailed tests was considered statistically significant. Data analysis was performed using the statistical package of IBM SPSS Statistics for Windows, Version 21.0. (Armonk, NY: IBM Corp).

Results

3.1 Patient characteristics

One hundred twelve JMG patients (42 males, 70 females, male-to-female ratio 0.6) were identified. The average age of onset was 8.5 years (range 0-20 years). The peak age of onset was biphasic: one peak was before the age of 5 and the other peak occurred during adolescence.

The most common symptoms were ptosis in 108 (96.4%) patients followed by diurnal symptom change in 61 (54.5%), muscle weakness in 24 (21.4%), double vision in 23 (20.5%), bulbar palsy in 18 (16.1%), respiratory symptoms in 10 (8.9%), head deviation in 3 (2.7%), ophthalmoplegia in 2 (1.8%), and facial palsy in 1 (0.9%) patient.

Clinical classification of the disease severity at onset was evaluated as class I in 88 (78.6%), class II in 13 (11.64%), class III in 3 (2.7%), class IV in 4 (3.6%) and class V in 4 (3.6%) patients. The age of onset for ocular type MG (n= 88) was younger than that for systemic type (n= 24) (7.29 ± 6.17 vs. 13.07 ± 4.71, P=0.001). Four patients had a family history of MG. Three patients had a family history of thyroid diseases.

Serologic tests were performed in 107 (95.5%) patients. Peak anti-acetylcholine receptor antibodies were ≥ 0.5 nmol/L in 60 (56%), 0.2-0.5 nmol/L in 11 (10%), and < 0.2 nmol/L in 35 patients (33%). Nine seronegative patients with onset of symptoms younger than the age of two were believed to have congenital MG. One seronegative patient had autoantibodies against MuSK and presented with systemic type and bulbar palsy.

Repetitive stimulation tests were performed in 47 patients, and 32 patients exhibited a typical decremental change. No correlation was observed between the anti-acetylcholine receptor value and
repetitive stimulation test results.

3.2 Outcome at two years and last outpatient clinic follow-up

After excluding patients without serum antibody data and one patient positive for anti-MuSK antibodies, a total of 54 patients followed up for over two years (range 24 to 258 months, mean 112 months) (Fig. 1). We compared the demographic data of JMG patients with different levels of anti-acetylcholine receptor antibodies, and no difference was observed (Table 1). In total, 42 patients (80%) were ocular type and 12 patients (20%) were generalized type. Nine (9/54, 16.7%) achieved complete remission without medication use at two years after diagnosis. Thirteen (24.1%) patients achieved complete remission during later follow-up periods. Thirty-two (59.3%) patients had improved symptoms but were maintained on oral medication, 5 (9.3%) patients were maintained on a high dosage of immunosuppressant, and 4 (7.3%) patients had worse symptoms. Fifty-two of 106 (49%) patients had incomplete follow-up over two years. No gender, age, disease severity, and intervention differences were observed between patients followed up for two years and those without.

3.3 Outcome versus anti-acetylcholine receptor antibody levels

We compared two-year outcomes among 54 JMG patients using receiver operating characteristic curve (ROC) curves with anti-acetylcholine receptor antibodies at different levels. ROC curves of primary and secondary outcomes are presented in Fig. 2 and 3. Analyses revealed that a serum cut-off level of 0.2 nmol/L serves as an optimal predictive value at two years after diagnosis (sensitivity: 80%, specificity: 66%, PPV: 92%, NPV: 40%) (Table 2) and at last outpatient clinic (sensitivity: 83%, specificity: 57%, PPV: 85%, NPV: 53%) (Table 3). JMG patients with negative anti-acetylcholine receptor antibodies (< 0.2 nmol/L) were significantly more likely to achieve complete remission compared with those with antibodies ≥ 0.2 nmol/L at two years (6/15 [40%] vs. 3/39 [7.7%], 95% confidence interval [CI] 1.670 to 38.323) (Table 2, Fig. 4). In addition, JMG patients with anti-acetylcholine receptor antibodies less than 0.2 nmol/L exhibited a higher rate of complete remission compared with those with antibody > 0.2 nmol/L at last out-patient visit (8/15 [53.3%] vs. 5/39 [12.8%], 95% CI 2.367 to 20.704) (Table 3, Fig. 4). After adjustment for age, gender, classification and thymectomy operation, the clinical outcome exhibited a significant difference if we used a serum level
of 0.2 nmol/L as a cut-off (Table 4).

3.4 Clinical fluctuations

Four boys (aged 0.5 years, 1.5 years, 2.5 years and 7.3 years) with initial anti-acetylcholine levels less than 0.2 nmol/L became positive later (0.25 nmol/L, 12.5 nmol/L, 2.19 nmol/L and 11.1 nmol/L). The occurrence of seroconversion was detected 11, 19, 107, and 85 months after clinical onset, respectively. One of the 4 patients achieved complete remission at 2 years but developed symptom relapse, and the other 3 were maintained on oral medication throughout the study course.

3.5 Comorbidity

Comorbid diseases included Graves’ disease in 11 (9.8%) patients, Hashimoto disease in 2 (1.8%), systemic lupus erythematosus in 1 (0.9%), and rheumatic arthritis in 1 (0.9%) patient.

We analyzed the characteristics of 13 patients with comorbid autoimmune thyroid disease. Nine (69%) patients were females, and the mean onset age was older than JMG patients without comorbid autoimmune thyroid disease (11.8 ± 5.8 years old vs. 8.0 ± 6.3 years old, 95% CI 0.018 to 7.33). Ten (77%) patients had ocular type MG. Two had a family history of hyperthyroidism, and two had a family history of MG. In 10 (77%) patients, comorbid autoimmune thyroid diseases were diagnosed at or after the JMG diagnosis was made. Patients with anti-acetylcholine antibody serum levels < 0.2 nmol/L were less likely to have autoimmune thyroid disease (1/35 [2.9%] vs. 12/71 [16.9%], 95% CI 0.018 to 1.161). No correlation found using a cut-off level of 0.5 nmol/L.

3.6 Pharmacologic and surgical treatment

Forty-six of 112 (41.1%) patients received both cholinesterase inhibitors and steroids, 35 (31.3%) patients received cholinesterase inhibitors only, 5 (4.5%) patients received steroids only, and 8 (7.1%) patients did not receive any medication.

Eighteen of 112 (11%) patients received thymectomy, and 16 (16/18, 90%) were female. Patients manifesting with initial systemic MG were more likely to require thymectomy than those with initial ocular MG (12/24 [50%] vs. 6/88 [6.8%], 95% CI 4.31 to 43.49). No difference in the primary and secondary outcomes was observed between patients who received both or either cholinesterase inhibitors and steroids or who underwent thymectomy.
Discussion

Our study demonstrated that overall prognosis for remission is fair at 2 years since diagnosis (9/54, 16.7%) and in a longer clinical observation (13/54, 23.6%) in JMG. The remission rate in our cohort is compatible to previous studies, demonstrating that the remission rate in JMG was approximately 22.2% to 30% depending on the follow-up period [1,2,6,7,12]. We found that JMG patients with anti-acetylcholine receptor antibodies less than 0.2 nmol/L exhibited increased complete remission rate both at 2 years and even during a longer observation period. Furthermore, the optimal predictive value for clinical outcomes was found using cut-off value of 0.2 nmol/L but not 0.5 nmol/L. To the best of our knowledge, the current study is the first to apply the lack of the presence of anti-acetylcholine receptor antibodies as a predictive parameter for JMG patients.

Measurement of anti-acetylcholine receptor antibodies is important to establish the diagnosis. The relationship between antibodies level and outcome has been discussed. Afifi and Bell et al. [9]. {Afifi, 1993 #79} {Afifi, 1993 #79} {Afifi, 1993 #79} {Afifi, 1993 #79} first studied 17 JMG patients and revealed that the negative serology group likely became medication-free (2/6 [33%] vs. 2/11 [18%], P=0.58), but the result was not significant. A larger study group from Andrew et al. revealed no difference in frequency of remission between anti-acetylcholine receptor antibody-positive and antibody-negative patients [1]. Nevertheless, the study of Andrew’s overall remission rate was relatively lower, and our study participants were mostly Chinese patients. Another adult MG study revealed that female sex, late onset and positivity for anti-acetylcholine receptor antibodies were associated with progression from ocular MG to generalized MG [12]. Some of seronegative patients had other antibodies, such as cortactin and lipoprotein receptor-related protein 4. Result revealed these patients have better outcome [5]. This might explain potentially better outcome of our seronegative JMG.

Different cut-off values of anti-acetylcholine receptor antibodies were used in our study to predict outcome. We demonstrated that 0.2 had a better predictive value compared with 0.5. Although the cut-off value of 0.5 nmol/L is now widely used, as 0.2 nmol/L was used previously, for diagnosis of the MG population due to high specificity up to 99.99% [13], nonwhite MG sera were excluded in the
study for analysis of the cut-off value. In addition, the age of included patients indicates that most patients had adult onset MG. Chiu et al. demonstrated that Chinese patients with MG had lower anti-acetylcholine receptor antibody values, accounting for the increased frequency of ocular cases compared with that noted in Caucasians [14]. Another recent study enrolled 327 JMG Chinese patients and found the anti-acetylcholine receptor antibody level was reduced in ocular type MG compared with the generalized type [15]. However, these studies did not identify a clear correlation between antibody level and prognosis. We proposed 0.2 nmol/L as a better predictive cut-off value for JMG in the Chinese population.

Factors related to remission have been discussed in many studies. Prepubertal children exhibit increased rates of spontaneous remission compared with postpubertal individuals [1]. Patients who received thymectomy also likely exhibit a better prognosis [6,12]. MuSK myasthenia gravis also had an increased risk of respiratory crises [4]. We excluded one patient positive for anti-MUSK antibodies from multiple logistic regression to adjust for factors, including age, sex, thymectomy and disease severity, and the result remained significant. Anti-acetylcholine receptor antibodies levels were related to the remission rate in two years and longer follow-up.

Four patients had initial serology less than 0.2 nmol/L and then underwent seroconversion with recurrent symptoms or persist medication use. A previous study demonstrated that spontaneous elevation or normalization of antibodies was not uncommon. Up to 41% of the seronegative patients may become seropositive in 1 to 5 years as reported by Anlar et al [10]. We used the peak serology for the primary exposure variable to avoid “false negative”. The re-evaluation of serum antibodies against the acetylcholine receptor might be helpful if patients had initial anti-acetylcholine receptor antibody values less than 0.2 nmol/L but had persist symptoms or recurrent symptoms.

The most common autoimmune disease comorbid with JMG in our study was autoimmune thyroid disease, which was similar to previous study [6,16-18]. We observed that the characteristic features of JMG comorbid with autoimmune thyroid disease were female patients, older onset of symptoms, and positive family history of autoimmune disease. We also observed that anti-acetylcholine receptor antibodies less than 0.2 nmol/L were less likely to be comorbid with autoimmune thyroid disease. In
contrast, Chen et al. demonstrated that adult MG patients with autoimmune thyroid disease exhibited a slightly lower seropositive rate for anti-acetylcholine receptor antibody (70.2% vs. 75.5%) compared with patients without autoimmune thyroid disease [18]. This finding indicates that the pathogenesis of MG might be different between juvenile and adult onset.

This study has some limitations. First, some antibodies were measured post-immune therapy. In addition, the immunotherapy factor was not adjusted given the small sample size. Second, immunoassays for other antibodies, including muscle-specific kinase, cortactin and lipoprotein receptor-related protein 4, were not routinely performed in our hospital. In addition, Cruz et al. used cell-based assays to demonstrate that serum negative patients may exhibit an improved diagnosis of clustered anti-acetylcholine receptor antibodies in serum negative MG [19]. Third, 4 of 15 JMG patients were negative for serum antibodies but eventually yield an equivocal or positive result. We require an even longer observation period and a larger population to estimate the true negative group in JMG.

Conclusions
Our findings demonstrated that anti-acetylcholine receptor antibodies are not only a diagnostic marker but also an acceptable predictive marker in patients with JMG. We suggest that patients with peak anti-acetylcholine receptor antibody levels less than 0.2 nmol/L exhibited better prognosis and less comorbid autoimmune thyroid diseases.

Abbreviations

Abbreviations
JMG: Juvenile myasthenia gravis; MG: myasthenia gravis; ROC: Receiver operating characteristic; CSR: complete symptom remission; MUSK: muscle-specific kinase; PPV: positive predictive values; NPV: negative predictive values

Declarations

Acknowledgements
The authors wish to thank the Chang Gung Children’s Hospital Study Group for Children with Encephalitis/Encephalopathy Related Status Epilepticus and Epilepsy (CHEESE) study group at the
Department of Pediatric Neurology of Chang Gung Children’s Hospital for assistance with medical record analysis.

**Funding**

None

**Availability of data and materials**

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

**Authors’ contributions**

J JL, KLL and CCC conceived and designed the research. IJC, YSW, SYL and CCC acquired the data. CCC, ICS, IJC, HSW, SSK, YJC analyzed and interpreted the data. CCC, ICS draft the manuscript. IJC, KLL, HSW, MYH, PCH and MLC made critical revisions of the manuscript.

All authors approved the final manuscript.

**Ethics approval and consent to participate**

This study obtained ethical approval from the institutional review board of the Chang Gung Memorial Hospital (IRB No 201700494B0). This is a retrospective study, no inform consent was made. All the identifiable codes was encrypted, cannot recognize the identity of the patients. There is no risk of information leakage.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interest

**References**

1. Andrews PI, Massey JM, Howard JF, Jr., Sanders DB. Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis. Neurology. 1994;44(7):1208-14.

2. Finnis MF, Jayawant S. Juvenile myasthenia gravis: a paediatric perspective. Autoimmune Dis. 2011;2011:404101.
3. Evoli A. Acquired myasthenia gravis in childhood. Curr Opin Neurol. 2010;23(5):536-40.

4. Takahashi Y, Sugiyama M, Ueda Y, Itoh T, Yagyu K, Shiraishi H, et al. Childhood-onset anti-MuSK antibody positive myasthenia gravis demonstrates a distinct clinical course. Brain Dev. 2012;34(9):784-6.

5. Cortes-Vicente E, Gallardo E, Martinez MA, Diaz-Manera J, Querol L, Rojas-Garcia R, et al. Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin. JAMA Neurol. 2016;73(9):1099-104.

6. Lindner A, Schalke B, Toyka VK. Outcome in juvenile-onset myasthenia gravis: a retrospective study with long-term follow-up of 79 patients. J Neurol. 1997;244(8):515-20.

7. Ashraf VV, Talby AB, Veerendrakumar M, Rao S. Myasthenia gravis in children: a longitudinal study. Acta Neurol Scand. 2006;114(2):119-23.

8. Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo H-C, Marx A, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med. 2016;375(6):511-22.

9. Afifi AK, Bell WE. Tests for juvenile myasthenia gravis: comparative diagnostic yield and prediction of outcome. J Child Neurol. 1993;8(4):403-11.

10. Anlar B, Senbil N, Kose G, Degerliyurt A. Serological follow-up in juvenile myasthenia: clinical and acetylcholine receptor antibody status of patients followed for at least 2 years. Neuromuscul Disord. 2005;15(5):355-7.

11. Jaretzki A, 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg. 2000;70(1):327-34.

12. Rodriguez M, Gomez MR, Howard FM, Jr., Taylor WF. Myasthenia gravis in children:
long-term follow-up. Ann Neurol. 1983;13(5):504-10.

13. Somnier FE. Clinical implementation of anti-acetylcholine receptor antibodies. J Neurol Neurosurg Psychiatry. 1993;56(5):496-504.

14. Chiu HC, Vincent A, Newsom-Davis J, Hsieh KH, Hung T. Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians. Neurology. 1987;37(12):1854-7.

15. Huang X, Li Y, Feng H, Chen P, Liu W. Clinical Characteristics of Juvenile Myasthenia Gravis in Southern China. Front Neurol. 2018;9:77.

16. Kanazawa M, Shimohata T, Tanaka K, Nishizawa M. Clinical features of patients with myasthenia gravis associated with autoimmune diseases. Eur J Neurol. 2007;14(12):1403-4.

17. VanderPluym J, Vajsar J, Jacob FD, Mah JK, Grenier D, Kolski H. Clinical characteristics of pediatric myasthenia: a surveillance study. Pediatrics. 2013;132(4):e939-44.

18. Chen YL, Yeh JH, Chiu HC. Clinical features of myasthenia gravis patients with autoimmune thyroid disease in Taiwan. Acta Neurol Scand. 2013;127(3):170-4.

19. Rodriguez Cruz PM, Al-Hajjar M, Huda S, Jacobson L, Woodhall M, Jayawant S, et al. Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis. JAMA Neurol. 2015;72(6):642-9.

Tables

Table 1. Demographic data of 54 juvenile myasthenia gravis patients with different levels of AchR Ab

| AchR Ab titer | AchR Ab titer ≥ 0.2 and < 0.5 nmol/L (n=8) | AchR Ab titer ≥ 0.5 nmol/L |
|---------------|-------------------------------------------|---------------------------|
| < 0.2 nmol/L (n=15) |                                           |                           |
| n (%)        | n (%)                                     | n (%)                     |
| Sex          | Female | 7 (46) | 4 (50) | 19 (61) |
|--------------|--------|--------|--------|---------|
|              | Male   | 8 (54) | 4 (50) | 12 (39) |
| Age          | <10 year | 8 (53) | 6 (75) | 22 (71) |
|              | 11~20 year | 7 (46) | 2 (25) | 9 (29)  |
| Symptoms at onset |        |        |        |         |
| Ptosis       | 15 (100)| 8 (100)| 29 (94)|         |
| Diurnal change | 10 (67)| 4 (50) | 19 (61)|         |
| Diplopia     | 5 (33) | 2 (25) | 4 (13) |         |
| Bulbar sign  | 3 (23) | 0 (0)  | 5 (19) |         |
| Respiratory symptoms | 1 (7) | 0 (0)  | 3 (11) |         |
| Clinical subtype |       |        |        |         |
| Ocular type  | 10 (67)| 8 (100)| 24 (77)|         |
| Generalized type | 5 (33)| 0 (0)  | 7 (23) |         |
| #MGFA classification |     |        |        |         |
| I            | 10 (67)| 8 (100)| 24 (77)|         |
| II           | 4 (27) | 0 (0)  | 6 (10) |         |
| Class | Co-morbid diseases | | | |
|-------|-------------------|---|---|---|
| III   | Thymus hyperplasia | 6 (40) | 3 (37.5) | 10 (32) |
| IV    | Hyperthyroidism | 1 (6.7) | 1 (13) | 6 (19) |
| V     | Malignant thymoma | 0 | 0 | 1 (3) |
|       | Treatment | | | |
| No treatment | 1 (6.7) | 0 | 0 | |
| Thymectomy | 2 (13) | 2 (25) | 7 (23) | |
| Prednisolone only | 1 (6.7) | 0 | 2 (6.5) | |
| Anti-cholinergic regimen only | 6 (40) | 4 (50) | 7 (23) | |
| Both | 5 (33) | 2 (25) | 15 (48) | |

**Abbreviations:** AchR Ab, acetylcholine receptor antibodies
*Class I, ocular MG and all other muscle strength is normal; Class II, mild weakness affecting other than ocular muscles; Class III, moderate weakness affecting other than ocular muscles; Class IV, severe weakness affecting other than ocular muscles; Class V, intubation, with or without mechanical ventilation.*
Table 2. Comparison of AchR Ab cut-off levels associate to outcome at 2 years after diagnosis

| Use 0.2 as cut-off | Positive | Negative | P    | Sen | Spe |
|--------------------|----------|----------|------|-----|-----|
| No CSR             | n (%)    | n (%)    | 0.010* | 80 (65.4 - 90.4) | 66.7 (29.9 - 92.5) |
| CSR                | 3 (8)    | 6 (40)   |      |     |     |

Use 0.5 as cut-off

| No CSR | 28 (93) | 17 (71) | 0.148 | 62 (46.5 - 76.2) | 66.7 (29.9 - 92.5) |
| CSR    | 3 (7)   | 6 (29)   |      |     |     |

Abbreviations: AchR Ab, acetylcholine receptor antibodies, Sen: sensitivity, Spe: specificity, PPV: positive predictive value, complete symptom remission

Table 3. Comparison of AchR Ab cut-off levels associate to outcome at last outpatient after diagnosis

| Use 0.2 as cut-off | Positive | Negative | P    | Sen | Spe |
|--------------------|----------|----------|------|-----|-----|
| No CSR             | n (%)    | n (%)    | 0.004* | 82.9 (67.9 - 92.8) | 57.1 (28.9 - 82.3) |
| CSR                | 5 (13)   | 8 (53)   |      |     |     |

Use 0.5 as cut-off

| No CSR | 26 (87) | 15 (63) | 0.197 | 63.4 (46.9 - 77.9) | 57 (28.9 - 82.3) |
| CSR    | 5 (13)  | 8 (37)  |      |     |     |

Abbreviations: AchR Ab, acetylcholine receptor antibodies, Sen: sensitivity, Spe: specificity, PPV: positive predictive value, complete symptom remission

Table 4. Comparison of AchR Ab cut-off levels and outcome using logistic regression

| Unadjusted regression | OR | 95% CI | P    | OR |
|-----------------------|----|--------|------|----|
| No CSR at 2 years after diagnosis | > 0.2 vs. < 0.2 | 8.0 | 1.67 – 38.3 | 0.009* | 7.5 |
|                         | > 0.5 vs. < 0.5 | 3.3 | 0.72 – 14.9 | 0.122 |    |
| No CSR at last outpatient clinic | > 0.2 vs. < 0.2 | 7.8 | 1.95 – 31.0 | 0.004* | 6.3 |
|                         | > 0.5 vs. < 0.5 | 2.8 | 0.77 – 10.0 | 0.120 |    |

Abbreviations: AchR Ab, acetylcholine receptor antibodies, adjusted of sex, age, class and thymectomy operation

Figures
Flowchart of study exclusion criteria. Patients who did not complete follow-up for two years or who had antibodies other than anti-acetylcholine receptor antibodies were excluded.
Receiver operating characteristic (ROC) curve of the outcome at 2 years using a cut-off value of 0.2 nmol/L. The area under the ROC curve is 0.73, suggesting fair accuracy.
Receiver operating characteristic curve of the outcome at last outpatient clinic using a cut-off value of 0.2 nmol/L. The area under the ROC curve is 0.76, suggesting fair accuracy.
Figure 4

Flowchart of outcomes of juvenile myasthenia gravis evaluated at 2 years and last outpatient clinic (average 9 years) after diagnosis. # complete symptom remission (CSR) rate, the cessation of medication for at least 1 year without symptoms.